$159.00
4.262.75%
Last update: 12:51 PM
15 minutes delayed
Comments
Loading...
BeiGene
BGNENASDAQ
BeiGene (NASDAQ:BGNE) Stock, Analyst Ratings, Price Targets, Forecasts
BeiGene Ltd has a consensus price target of $271.46 based on the ratings of 14 analysts. The high is $431 issued by Bernstein on October 12, 2021. The low is $152.5 issued by B of A Securities on July 9, 2024. The 3 most-recent analyst ratings were released by B of A Securities, TD Cowen, and TD Cowen on July 9, 2024, May 9, 2024, and April 24, 2024, respectively. With an average price target of $214.17 between B of A Securities, TD Cowen, and TD Cowen, there's an implied 34.70% upside for BeiGene Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
TD Cowen
Bernstein
JP Morgan
Guggenheim
1calculated from analyst ratings
Analyst Ratings for BeiGene
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/09/2024 | Buy Now | -4.09% | B of A Securities | David Li | $180 → $152.5 | Maintains | Neutral | Get Alert |
| 05/09/2024 | Buy Now | 59.75% | TD Cowen | Yaron Werber | $236 → $254 | Maintains | Buy | Get Alert |
| 04/24/2024 | Buy Now | 48.43% | TD Cowen | Yaron Werber | $235 → $236 | Maintains | Buy | Get Alert |
| 04/08/2024 | Buy Now | 3.33% | B of A Securities | David Li | $179.3 → $164.3 | Maintains | Neutral | Get Alert |
| 03/27/2024 | Buy Now | 1.26% | Bernstein | Rebecca Liang | $196 → $161 | Maintains | Market Perform | Get Alert |
| 03/19/2024 | Buy Now | 16.98% | JP Morgan | Jessica Fye | $184 → $186 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 116.98% | Guggenheim | Michael Schmidt | $350 → $345 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 16.35% | JP Morgan | Jessica Fye | → $185 | Assumes | → Overweight | Get Alert |
| 10/26/2023 | Buy Now | 79.25% | Citigroup | Yigal Nochomovitz | $290 → $285 | Maintains | Buy | Get Alert |
| 09/21/2023 | Buy Now | 82.39% | Citigroup | Yigal Nochomovitz | $285 → $290 | Maintains | Buy | Get Alert |
| 09/20/2023 | Buy Now | 33.33% | B of A Securities | David Li | $224.13 → $212 | Maintains | Neutral | Get Alert |
| 09/12/2023 | Buy Now | 62.89% | Macquarie | Jake Lynch | → $259 | Initiates | → Outperform | Get Alert |
| 09/12/2023 | Buy Now | 62.89% | RBC Capital | Jake Lynch | → $259 | Initiates | → Outperform | Get Alert |
| 08/29/2023 | Buy Now | 100.63% | Morgan Stanley | Matthew Harrison | $321 → $319 | Maintains | Overweight | Get Alert |
| 08/17/2023 | Buy Now | 80.5% | Jefferies | Kelly Shi | → $287 | Initiates | → Buy | Get Alert |
| 08/07/2023 | Buy Now | 88.68% | JP Morgan | Xiling Chen | $297 → $300 | Maintains | Overweight | Get Alert |
| 07/17/2023 | Buy Now | 72.96% | Citigroup | Yigal Nochomovitz | → $275 | Initiates | → Buy | Get Alert |
| 06/30/2023 | Buy Now | 23.27% | Bernstein | Rebecca Liang | $335 → $196 | Downgrade | Outperform → Market Perform | Get Alert |
| 04/12/2023 | Buy Now | 65.6% | B of A Securities | David Li | $230.1 → $263.3 | Maintains | Neutral | Get Alert |
| 02/28/2023 | Buy Now | 120.13% | Guggenheim | Michael Schmidt | → $350 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 64.78% | Cowen & Co. | Yaron Weber | $213 → $262 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | 101.89% | Morgan Stanley | Matthew Harrison | $325 → $321 | Maintains | Overweight | Get Alert |
| 01/24/2023 | Buy Now | 104.4% | Morgan Stanley | Matthew Harrison | $295 → $325 | Maintains | Overweight | Get Alert |
| 01/20/2023 | Buy Now | 120.13% | Guggenheim | Michael Schmidt | $290 → $350 | Maintains | Buy | Get Alert |
| 01/20/2023 | Buy Now | 88.68% | SVB Leerink | Andrew Berens | $236 → $300 | Maintains | Outperform | Get Alert |
| 12/12/2022 | Buy Now | 48.43% | SVB Leerink | Andrew Berens | $210 → $236 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 32.08% | SVB Leerink | Andrew Berens | $200 → $210 | Maintains | Outperform | Get Alert |
| 10/13/2022 | Buy Now | 85.53% | Morgan Stanley | Matthew Harrison | $290 → $295 | Maintains | Overweight | Get Alert |
| 10/13/2022 | Buy Now | 28.93% | Guggenheim | Michael Schmidt | → $205 | Upgrade | Neutral → Buy | Get Alert |
| 10/13/2022 | Buy Now | 25.79% | SVB Leerink | Andrew Berens | $177 → $200 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/09/2022 | Buy Now | 86.16% | JP Morgan | Xiling Chen | → $296 | Assumes | → Overweight | Get Alert |
| 07/15/2022 | Buy Now | 84.28% | Morgan Stanley | Matthew Harrison | $300 → $293 | Maintains | Overweight | Get Alert |
| 05/09/2022 | Buy Now | 88.68% | Morgan Stanley | Matthew Harrison | $338 → $300 | Maintains | Overweight | Get Alert |
| 04/12/2022 | Buy Now | 112.58% | Morgan Stanley | Matthew Harrison | $330 → $338 | Maintains | Overweight | Get Alert |
| 03/17/2022 | Buy Now | 11.32% | SVB Leerink | Andrew Berens | $300 → $177 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/28/2022 | Buy Now | 107.55% | Morgan Stanley | Matthew Harrison | $360 → $330 | Maintains | Overweight | Get Alert |
| 02/28/2022 | Buy Now | 88.68% | SVB Leerink | Andrew Berens | $334 → $300 | Maintains | Outperform | Get Alert |
| 01/18/2022 | Buy Now | 126.42% | Morgan Stanley | Matthew Harrison | $407 → $360 | Maintains | Overweight | Get Alert |
| 10/14/2021 | Buy Now | 160.38% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
| 10/12/2021 | Buy Now | 171.07% | Bernstein | — | — | Initiates | → Outperform | Get Alert |
| 08/16/2021 | Buy Now | 155.97% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for BeiGene (BGNE) stock?
The latest price target for BeiGene (NASDAQ:BGNE) was reported by B of A Securities on July 9, 2024. The analyst firm set a price target for $152.50 expecting BGNE to fall to within 12 months (a possible -4.09% downside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BeiGene (BGNE)?
The latest analyst rating for BeiGene (NASDAQ:BGNE) was provided by B of A Securities, and BeiGene maintained their neutral rating.
When was the last upgrade for BeiGene (BGNE)?
The last upgrade for BeiGene Ltd happened on October 13, 2022 when Guggenheim raised their price target to $205. Guggenheim previously had a neutral for BeiGene Ltd.
When was the last downgrade for BeiGene (BGNE)?
The last downgrade for BeiGene Ltd happened on June 30, 2023 when Bernstein changed their price target from $335 to $196 for BeiGene Ltd.
When is the next analyst rating going to be posted or updated for BeiGene (BGNE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeiGene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeiGene was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.
Is the Analyst Rating BeiGene (BGNE) correct?
While ratings are subjective and will change, the latest BeiGene (BGNE) rating was a maintained with a price target of $180.00 to $152.50. The current price BeiGene (BGNE) is trading at is $159.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.